Literature DB >> 7487142

FK506: therapeutic effects on lupus dermatoses in autoimmune-prone MRL/Mp-lpr/lpr mice.

F Furukawa1, S Imamura, M Takigawa.   

Abstract

The effects of FK506, a new immunosuppressive agent, on the development of lupus dermatoses were investigated in the autoimmune-prone MRL/Mp-lpr/lpr (MRL/lpr) mouse, which is an animal model for the spontaneous development of skin lesions similar to those of human lupus erythematosus (LE). FK506 reduced the incidence of skin lesions, lupus nephritis, the titre of serum anti-double-stranded DNA antibodies and the massive T cell proliferation. The incidence and magnitude of IgG deposition at the dermoepidermal junction were not changed. These results suggest that FK506 is a promising immunosuppressive agent for the control of autoimmune skin diseases.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7487142     DOI： 10.1007/bf00374076

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN： 0340-3696            Impact factor:   3.017


  27 in total

Review 1.  FK 506 and autoimmune disease: perspective and prospects.

Authors:  A W Thomson; T E Starzl
Journal:  Autoimmunity       Date:  1992       Impact factor: 2.815

2.  The genetic contribution of the NZB mouse to the renal disease of the NZB x NZW hybrid.

Authors:  J G Knight; D D Adams; H D Purves
Journal:  Clin Exp Immunol       Date:  1977-05       Impact factor: 4.330

3.  Effects of FK-506 on collagen arthritis in mice.

Authors:  K Takagishi; M Yamamoto; A Nishimura; G Yamasaki; N Kanazawa; T Hotokebuchi; N Kaibara
Journal:  Transplant Proc       Date:  1989-02       Impact factor: 1.066

4.  FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics.

Authors:  T Kino; H Hatanaka; M Hashimoto; M Nishiyama; T Goto; M Okuhara; M Kohsaka; H Aoki; H Imanaka
Journal:  J Antibiot (Tokyo)       Date:  1987-09       Impact factor: 2.649

5.  Effect of FK-506, a novel immunosuppressive drug on murine systemic lupus erythematosus.

Authors:  K Takabayashi; T Koike; K Kurasawa; R Matsumura; T Sato; H Tomioka; I Ito; T Yoshiki; S Yoshida
Journal:  Clin Immunol Immunopathol       Date:  1989-04

6.  High levels of anti-mitochondrial antibodies in MRL mice. Influence of anti-DNA antibodies on anti-mitochondrial antibodies measured by an enzyme-linked immunosorbent assay.

Authors:  G Ohshio; F Furukawa; H Yoshioka; Y Taki; T Manabe; K Ozawa; T Tobe; Y Hamashima
Journal:  Microbiol Immunol       Date:  1987       Impact factor: 1.955

7.  Ultrastructural observations of skin lesions in MRL mice--dermal infiltrations and capillary changes.

Authors:  Y Horiguchi; F Furukawa; S Imamura
Journal:  J Dermatol       Date:  1986-12       Impact factor: 4.005

8.  CS-A therapy in MRL-lpr/lpr mice: amelioration of immunopathology despite autoantibody production.

Authors:  J D Mountz; H R Smith; R L Wilder; J P Reeves; A D Steinberg
Journal:  J Immunol       Date:  1987-01-01       Impact factor: 5.422

9.  Effects of cyclosporin A on autoimmune disease in MRL/1 and BXSB mice.

Authors:  J H Berden; P Faaber; K J Assmann; T P Rijke
Journal:  Scand J Immunol       Date:  1986-10       Impact factor: 3.487

10.  Ultrastructural observations of skin lesions in MRL mice--dermoepidermal junction.

Authors:  Y Horiguchi; F Furukawa; Y Hamashima; S Imamura
Journal:  Arch Dermatol Res       Date:  1984       Impact factor: 3.017
View more
  4 in total

1.  Chronic Inflammation Promotes Skin Carcinogenesis in Cancer-Prone Discoid Lupus Erythematosus.

Authors:  Anniek Zaalberg; Sara Moradi Tuchayi; Amir H Ameri; Kenneth H Ngo; Trevor J Cunningham; Jean-Pierre Eliane; Maia Livneh; Thomas D Horn; Ilana S Rosman; Amy Musiek; Milan J Anadkat; Shadmehr Demehri
Journal:  J Invest Dermatol       Date:  2018-07-17       Impact factor: 8.551

Review 2.  Topical tacrolimus and pimecrolimus in the treatment of cutaneous lupus erythematosus: an evidence-based evaluation.

Authors:  Thrasivoulos George Tzellos; Dimitrios Kouvelas
Journal:  Eur J Clin Pharmacol       Date:  2007-12-20       Impact factor: 2.953

Review 3.  Molecular therapies for systemic lupus erythematosus: clinical trials and future prospects.

Authors:  Fanny Monneaux; Sylviane Muller
Journal:  Arthritis Res Ther       Date:  2009-06-30       Impact factor: 5.156

4.  Nephroprotective Potential of Mesenchymal Stromal Cells and Their Extracellular Vesicles in a Murine Model of Chronic Cyclosporine Nephrotoxicity.

Authors:  María José Ramírez-Bajo; Javier Martín-Ramírez; Stefania Bruno; Chiara Pasquino; Elisenda Banon-Maneus; Jordi Rovira; Daniel Moya-Rull; Marta Lazo-Rodriguez; Josep M Campistol; Giovanni Camussi; Fritz Diekmann
Journal:  Front Cell Dev Biol       Date:  2020-05-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.